Home / Import refusals / F23-9339962-1/50002/1

F23-9339962-1/50002/1

Boehringer Ingelheim Pharma GmbH & Co. KG — FEI 3002806556

Recent inspections

  • 1208521 (VAI Thu Oct 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1053519 (VAI Fri May 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 962108 (VAI Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 921540 (NAI Fri Jan 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 877010 (NAI Fri Mar 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time))

Compliance actions

Other import refusals

  • AEK-9152797-6/10002/1 (Sun Jan 18 2026 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)
  • AEK-7894740-3/10002/1 (Tue Nov 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)
  • 799-8221344-1/10002/1 (Fri Nov 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)
  • AEK-7679375-9/20002/1 (Tue Oct 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)
  • F23-9339962-1/50002/2 (Wed Sep 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) — Drugs and Biologics)

Refusal Details

Date
September 3, 2025
Country
Germany
Product Category
Drugs and Biologics
Product Code
61PCY73 EMPAGLIFLOZIN (ANTI-DIABETIC)
Charges
75